Dyadic to Attend Multiple Industry Events in March

by B2i | Mar 6, 2025 | Press Releases

JUPITER, Fla., March 06, 2025 — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a biotechnology company focused on the efficient large-scale manufacture of...

Dyadic Provides Business Update; Dyadic to Attend the 43rd Annual J.P. Morgan Healthcare Conference

by B2i | Jan 6, 2025 | Press Releases

JUPITER, Fla., Jan. 06, 2025 — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a biotechnology company focused on the efficient large-scale manufacture of...

Dyadic Receives $3 Million Grant to Develop Cost-Effective Monoclonal Antibodies for RSV and Malaria Using C1 Platform Technology

by B2i | Nov 21, 2024 | Press Releases

Grant Received from the Bill & Melinda Gates Foundation to Fund Development of Affordable TherapeuticsJUPITER, Fla., Nov. 21, 2024 — Dyadic International, Inc. (NASDAQ: DYAI), a global biotechnology company, announced today that it has been awarded a $3...

Dyadic Announces Third Quarter 2024 Financial Results and Strategic Progress Across Key Markets

by B2i | Nov 12, 2024 | Press Releases

Highlights Revenue Milestones and Expands Alternative Protein & Pharmaceutical Partnerships with Dapibus™ & C1 Technology Platforms Alternative Proteins Demonstrated substantial revenue increase for Q3 2024, driven primarily by Dapibus™ license...

Dyadic to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

by B2i | Nov 4, 2024 | Press Releases

JUPITER, Fla., Nov. 04, 2024 — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scale manufacture of...